



32/D  
AF/NE  
E. Williams  
7-16-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Zeicher	)	Group Art Unit 1635
Appl. No.	:	08/807,500	)	
Filed	:	February 27, 1997	)	
For	:	NUCLEOTIDE SEQUENCE FOR TREATING CANCER AND INFECTION	)	
Examiner	:	McGarry, S.	)	

RECEIVED  
JUL 12 2002  
TECH CENTER 1600/2900

**AMENDMENT AFTER FINAL and SEQUENCE SUBMISSION STATEMENT**

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202  
ATTENTION BOX: AF

Dear Sir:

In response to the Office Action mailed from the United States Patent and Trademark Office on January 11, 2002 (Paper No. 25), please amend the above-referenced application as follows:

**IN THE SPECIFICATION:**

**On page 47, please amend the paragraph beginning at line 18 as follows:**

The fragment HindIII-Sspl containing the 3'end region coding for the capsids of MVM in plasmid PMM984 is inserted in the corresponding sites of pUC19. The Sspl site is transformed in a NsiI site by the addition of the linker NsiI (5'TGCATGCATGCA-3' SEQ ID NO: 1). The HindIII-NsiI fragment is inserted in the HindIII et NsiI site of the plasmid pPolyA (where the HindIII site was transformed into a NsiI site) according to the method of Spegelaere P., et al, (Journal of Virology 65: 4919, (1991)) in front of the SV40 polyadenylation signal.